|
|
PharmaVitae 2004: King Pharmaceuticals Global AnalysisPublished by: Datamonitor Published: May. 4, 2004 - 95 Pages Table of ContentsTABLE OF CONTENTS CHAPTER 1 EXECUTIVE SUMMARY 4 Key findings 4 Current positioning: competitive outlook 2003 5 Future performance: growth drivers and resistors 2004-10 6 Evolution in therapeutic focus: 2003 - 10 7 Key issues facing King Pharmaceuticals: 2004 - 10 8 Strategic outlook 9 CHAPTER 2 COMPANY STRATEGY 17 Introduction to King Pharmaceuticals 18 Assessment of strategic position 18 Strengths 19 Weaknesses 20 Opportunities 21 Threats 22 Therapeutic foci 23 R&D productivity 26 Development opportunities 27 Organic growth 27 Partnerships/licensing 28 Mergers and acquisitions 28 Geographical expansion 29 Implications of financial position 30 CHAPTER 3 PORTFOLIO AND PIPELINE ANALYSIS 31 Therapy area focus in 2003 32 Business development by therapy area 34 Forecast revenue stream, 2004-10 37 Therapy area forecasts to 2010 37 Cardiovascular franchise 40 Marketed products 40 R&D compounds 49 Cardiovascular portfolio sales forecasts and forecast revenue growth 51 CNS franchise 52 Marketed products 52 R&D compounds 59 CNS portfolio sales forecasts and forecast revenue growth 60 Diabetes and endocrinology franchise 61 Marketed products 61 R&D compounds 66 Diabetes and endocrinology portfolio sales forecasts and forecast revenue growth 67 Infectious disease franchise 68 Marketed products 68 R&D compounds 71 Infectious disease portfolio sales forecasts and forecast revenue growth 72 Women’s health franchise 73 Marketed products 73 R&D compounds 77 Women’s health portfolio sales forecasts and forecast revenue growth 78 Other products 78 Marketed products 79 R&D compounds 81 Other products sales forecasts and forecast revenue growth 81 CHAPTER 4 CORPORATE DEVELOPMENT 83 Financial position, 2002 - 2003 84 Profitability, 1999-2003 84 Revenue growth 84 Cost structure 86 Liquidity, 1999-2003 87 2003 performance benchmarking 88 Business model clustering according to 2003 cost ratios 88 2003 growth and investment momentum 89 Key events shaping corporate activity, 1999-2003 91 Merger and acquisition activity 91 Corporate alliances and deals 92 Regulatory affairs 93 Other business development and news 93 CHAPTER 5 APPENDIX : SUPPORTING DATA 94 Financial data 94 Exchange rates 94 Methodology for therapy area forecasting 95 LIST OF TABLES Table 1: Breakdown of King Pharmaceuticals’s ethical sales by therapy area, 2002-03 32 Table 2: Forecast sales for King Pharmaceuticals’s major therapy areas, 2004-10 38 Table 3: King Pharmaceuticals’s marketed cardiovascular portfolio 41 Table 4: King Pharmaceuticals’s cardiovascular R&D pipeline, 2003 50 Table 5: Forecast sales for King Pharmaceuticals’s cardiovascular portfolio, 2004-10 51 Table 6: King Pharmaceuticals’s marketed CNS portfolio 52 Table 7: King Pharmaceuticals’s CNS R&D pipeline, 2003 59 Table 8: Forecast sales for King Pharmaceuticals’s CNS portfolio, 2004-10 60 Table 9: King Pharmaceuticals’s marketed diabetes and endocrinology portfolio 61 Table 10: King Pharmaceuticals’s diabetes and endocrinology R&D pipeline, 2003 66 Table 11: Forecast sales for King Pharmaceuticals’s diabetes and endocrinology portfolio, 2004-2010 67 Table 12: King Pharmaceuticals’s marketed infectious disease portfolio 68 Table 13: King Pharmaceuticals’s infectious disease R&D pipeline, 2003 71 Table 14: Forecast sales for King Pharmaceuticals’s infectious disease portfolio, 2004-10 73 Table 15: King Pharmaceuticals’s marketed women’s health portfolio 74 Table 16: King Pharmaceuticals’s women’s health R&D pipeline, 2003 77 Table 17: Forecast sales for King Pharmaceuticals’s women’s health portfolio, 2004-10 78 Table 18: King Pharmaceuticals’s other marketed products 79 Table 19: Forecast sales of King Pharmaceuticals’s other products portfolio, 2004-10 82 Table 20: King Pharmaceuticals’s revenues by division, 2002-03 85 Table 21: King Pharmaceuticals’s operating expenses, 2002-03 86 Table 22: Summary of King Pharmaceuticals’s historical M&A activity, 2003-2004 91 Table 23: Summary of King Pharmaceuticals’s historical agreements, 2003-04 92 Table 24: Exchange rates, 2003 94 LIST OF FIGURES Figure 1: Competitive positioning of King Pharmaceuticals within the pharmaceutical market, 2003 5 Figure 2: King Pharmaceuticals’s growth drivers and resistors, 2004-10 6 Figure 3: Evolution in therapeutic focus: 2003-10 7 Figure 4: King Pharmaceuticals’s R&D dependence 8 Figure 5: Assessment of King Pharmaceuticals’s strategic position, 2004 9 Figure 6: Development of King Pharmaceuticals’s therapeutic strategy, 2004-10 24 Figure 7: Combined company’s ethical sales breakdown, 2003 34 Figure 8: King Pharmaceuticals’s business development by therapy area 35 Figure 9: Forecast sales for King Pharmaceuticals’s major therapy areas, 2004-10 40 Figure 10: King Pharmaceuticals’s profitability stream, 1999-2003 84 Figure 11: King Pharmaceuticals’s liquid assets versus total liabilities, 1999-2003 87 Figure 12: R&D and S,G&A spend and COGS as a proportion of revenue, 2003 88 Figure 13: Benchmarking of financial strength, 2003 90 AbstractIntroductionThis analysis examines the current position and future outlook for King in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-7 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information Reasons to Purchase Understand the driving force behind King's 34.8% increase in revenues in 2003 Benchmark King's performance against key rivals in the ethical pharmaceutical sector Evaluate the success of King's "growth by acquisition" strategy Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||